Zealand Pharma A/S (OTCMKTS:ZLDPF) Receives Average Rating of “Strong Buy” from Analysts

Shares of Zealand Pharma A/S (OTCMKTS:ZLDPF) have received an average recommendation of “Strong Buy” from the seven ratings firms that are currently covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a hold recommendation, one has given a buy recommendation and five have given a strong buy recommendation to the company.

Several research firms have recently issued reports on ZLDPF. Zacks Research raised Zealand Pharma A/S from a “strong sell” rating to a “hold” rating in a research report on Monday, September 15th. Barclays raised Zealand Pharma A/S to a “strong-buy” rating in a research report on Monday, July 7th. Wells Fargo & Company raised Zealand Pharma A/S to a “strong-buy” rating in a research report on Thursday, July 24th. Finally, BNP Paribas raised Zealand Pharma A/S to a “strong-buy” rating in a research report on Tuesday, July 1st.

Zealand Pharma A/S Stock Performance

OTCMKTS:ZLDPF opened at $77.42 on Thursday. The stock has a 50-day simple moving average of $66.81 and a 200-day simple moving average of $64.57. The stock has a market cap of $5.50 billion, a P/E ratio of 5.44 and a beta of 0.74. Zealand Pharma A/S has a 1 year low of $49.98 and a 1 year high of $126.00. The company has a debt-to-equity ratio of 0.02, a quick ratio of 15.08 and a current ratio of 15.09.

Zealand Pharma A/S (OTCMKTS:ZLDPF) last released its quarterly earnings data on Thursday, August 14th. The company reported $16.06 earnings per share (EPS) for the quarter, missing the consensus estimate of $16.72 by ($0.66). The business had revenue of $1.43 billion for the quarter, compared to analyst estimates of $9.18 billion. Zealand Pharma A/S had a return on equity of 67.06% and a net margin of 73.90%. As a group, analysts anticipate that Zealand Pharma A/S will post -2.19 earnings per share for the current fiscal year.

Zealand Pharma A/S Company Profile

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon.